Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04524390 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Maralixibat in Biliary Atresia Response Post-Kasai
A Phase 2 study, sponsored by Mirum Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
NCT04524390 is a Phase 2 study that has completed, run by Mirum Pharmaceuticals. The registered enrollment target is 75 participants.
The verdict
NCT04524390, a Phase 2 study, has completed, sponsored by Mirum Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
Study Summary
A study to evaluate the efficacy and safety of maralixibat in infants with Biliary Atresia (BA) after Hepatoportoenterostomy (HPE, also known as the Kasai procedure).
Interventions
- OTHER Placebo
- DRUG Maralixibat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2021-07-08 |
| Est. Completion | 2024-02-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04524390
The ClinicalTrials.gov registry entry for NCT04524390 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mirum Pharmaceuticals, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04524390 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04524390 about?
NCT04524390 is a clinical study titled "Evaluation of Maralixibat in Biliary Atresia Response Post-Kasai". A study to evaluate the efficacy and safety of maralixibat in infants with Biliary Atresia (BA) after Hepatoportoenterostomy (HPE, also known as the Kasai procedure).
What is the current status of trial NCT04524390?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2021-07-08. Estimated completion is 2024-02-07.
What interventions are being tested in trial NCT04524390?
The interventions under investigation include: Placebo (OTHER), Maralixibat (DRUG).
Who is sponsoring clinical trial NCT04524390?
This trial is sponsored by Mirum Pharmaceuticals, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.